{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.07","upperLimit":"0.95","value":"0.25"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.44","upperLimit":"2.70","value":"1.09"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The overall survival was determined by grouping participants based upon their response based on RECIST. The groups are Complete Response(CR): All the cancerous lesion disappear, Partial Response (PR): All the measured lesions decrease by at least 30 percent, and Stable Disease(SD): No significant change in the disease burden. OS of complete response or partial response participants were compared to the reference group of stable disease participants in a Hazard Ratio(HR). If HR is greater than 1, the experimental group has a better outcome than the reference group. If HR is less than 1, the reference group has the better outcome.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 135 mg/m\\^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m\\^2 IV over 90 minutes; Doxorubicin 40 mg/m\\^2 IV over 20 minutes; treatment may repeat every 2 weeks for up to nine courses. Subcutaneous Injection of Pegfilgrastim on day 1 or 2 of each course, after chemotherapy.","id":"OG000","title":"Gemcitabine, Paclitaxel and Doxorubicin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Registration Date of each participant for up to three years or death whichever came first","title":"Overall Survival (OS) of Participants With a Continuous Complete Response, Partial Response and Stable Disease","type":"SECONDARY","unitOfMeasure":"Hazard Ratio"}